CDD-1274 is an ERalpha (Estrogen receptor alpha) variant inhibitor. CDD-1274 induces proteasomal degradation of ERalpha variants in breast cancer cell lines and causes Y537S ERalpha degradation. CDD-1274 potently blocks ligand-dependent and ligand-independent ER signaling in endocrine-resistant breast cancer cells. CDD-1274 can be used for the study of breast cancer[1].
Molecular Weight:
567.57
Formula:
C28H33F4N3O5
Target:
Estrogen Receptor/ERR
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
